Full Breakdown
Intellia’s In-Vivo CRISPR Therapy Cuts Hereditary Angioedema Attacks by 87% in Phase 3 Trial
4/28/2026, 9:29:37 PM
Phase 3 Trial Shows 87% Attack Reduction
In the HAELO Phase 3 trial, 80 hereditary angioedema patients were randomized 52-to-28 to receive a single 50 mg infusion of lonvo-z (lonvoguran ziclumeran) or placebo. Over six months, attack rates fell 87% versus placebo; treated patients averaged 0.26 attacks per month versus 2.10 for placebo. Sixty-two percent of lonvo-z recipients were attack-free and off prophylaxis, versus 11% on placebo.
In-Vivo CRISPR: First Human Success
Lonvo-z uses Nobel Prize-winning CRISPR to edit the KLKB1 gene in the liver, lowering kallikrein and bradykinin that cause swelling. The trial delivers the first Phase 3 data for any in-vivo CRISPR therapy, while the only FDA-approved CRISPR product, Vertex’s ex-vivo Casgevy, edits cells outside the body. This marks the first pathway for direct gene editing in patients.
Key Figures and Official Statements
Intellia Therapeutics of Cambridge, Massachusetts, leads development. CEO John Leonard called the data a “profound milestone” and stressed the edit’s permanence. Harvard Medical School professor Aleena Banerji called the therapy an “appealing option” if approved. CFO Edward Dulac said pricing will likely exceed existing prophylactics but cautioned that high cost could provoke payer resistance. Intellia has started a rolling biologics license application, targeting filing in the second half of 2026.
Safety, Criticism, and Market Risks
The trial reported mild-to-moderate adverse events, mainly infusion reactions, headache and fatigue; one Grade 2 ALT rise resolved in a week and no serious events occurred before the cutoff. A prior fatal liver-toxicity case in another Intellia CRISPR program led to an FDA hold, raising safety concerns. Analysts say six-month durability may not justify a premium price given existing HAE drugs and the mixed record of gene-therapy products such as BioMarin’s withdrawn hemophilia A therapy. Cantor analyst Steve Seedhouse called lonvo-z “probably a niche product.”
Regulatory Path and Future Outlook
Intellia’s rolling biologics license application, using a regenerative-medicine designation, enables ongoing FDA dialogue; the agency will review the submission later in 2026, with possible U.S. launch in early 2027 if approved. Additional HAELO data will be presented at European Academy of Allergy and Clinical Immunology Congress in Istanbul in June. Post-marketing studies will monitor long-term durability and liver safety.
Verbatim Quotes
- “When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we've had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you're actually changing a gene that causes disease,” — John Leonard, President and CEO, Intellia Therapeutics
- “I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it's permanent,” — John Leonard, President and CEO, Intellia Therapeutics
- “appealing option” — Aleena Banerji, Professor, Harvard Medical School and trial investigator
- “probably a niche product,” — Steve Seedhouse, Analyst, Cantor
